Filing Details

Accession Number:
0000899243-21-031627
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-04 17:12:05
Reporting Period:
2021-08-02
Accepted Time:
2021-08-04 17:12:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1861560 Nuvalent Inc. NUVL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657434 F. A. Andrew Hack C/O Bain Capital Life Sciences Investors
200 Clarendon Street
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2021-08-02 2,693,014 $0.00 2,693,014 No 4 C Indirect See footnotes
Class A Common Stock Acquisiton 2021-08-02 735,000 $17.00 3,428,014 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Series B Preferred Stock Disposition 2021-08-02 14,494,154 $0.00 2,693,014 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. Represents securities held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities").
  2. Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. As a result, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
  3. Each share of the Issuer's Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.
  4. On August 2, 2021, BCLS II Investco purchased 735,000 shares of the Issuer's Class A Common Stock at a price of $17.00 per share in the Issuer's initial public offering.